CO2021005502A2 - Compuestos, composiciones, y métodos para modular la actividad cdk9 - Google Patents
Compuestos, composiciones, y métodos para modular la actividad cdk9Info
- Publication number
- CO2021005502A2 CO2021005502A2 CONC2021/0005502A CO2021005502A CO2021005502A2 CO 2021005502 A2 CO2021005502 A2 CO 2021005502A2 CO 2021005502 A CO2021005502 A CO 2021005502A CO 2021005502 A2 CO2021005502 A2 CO 2021005502A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- compounds
- methods
- cdk9 activity
- modulate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Inhibidores de CDK9 que son derivados de pirazol[1,5-α]pirimidina y sales de los mismos, correspondientes a la fórmula (I).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752635P | 2018-10-30 | 2018-10-30 | |
US201962884993P | 2019-08-09 | 2019-08-09 | |
US201962910058P | 2019-10-03 | 2019-10-03 | |
PCT/US2019/058482 WO2020092314A1 (en) | 2018-10-30 | 2019-10-29 | Compounds, compositions, and methods for modulating cdk9 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021005502A2 true CO2021005502A2 (es) | 2021-09-20 |
Family
ID=70328627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0005502A CO2021005502A2 (es) | 2018-10-30 | 2021-04-27 | Compuestos, composiciones, y métodos para modular la actividad cdk9 |
Country Status (20)
Country | Link |
---|---|
US (2) | US11155560B2 (es) |
EP (1) | EP3873911A4 (es) |
JP (1) | JP7385658B2 (es) |
KR (1) | KR20210068597A (es) |
CN (1) | CN112996790B (es) |
AU (1) | AU2019370200A1 (es) |
BR (1) | BR112021008176A2 (es) |
CA (1) | CA3118472A1 (es) |
CO (1) | CO2021005502A2 (es) |
CR (1) | CR20210202A (es) |
DO (1) | DOP2021000066A (es) |
IL (1) | IL282254A (es) |
MA (1) | MA54092A (es) |
MD (1) | MD20210033A2 (es) |
MX (1) | MX2021004769A (es) |
PE (1) | PE20212196A1 (es) |
PH (1) | PH12021550857A1 (es) |
SG (1) | SG11202104229WA (es) |
WO (1) | WO2020092314A1 (es) |
ZA (1) | ZA202102609B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA54092A (fr) * | 2018-10-30 | 2021-09-08 | Kronos Bio Inc | Composés, compositions et procédés de modulation de l'activité de cdk9 |
US20230158159A1 (en) * | 2020-04-24 | 2023-05-25 | Massachusetts Institute Of Technology | Chimeric degraders of cyclin-dependent kinase 9 and uses thereof |
EP4240422A1 (en) * | 2020-11-05 | 2023-09-13 | Kronos Bio, Inc. | Compounds and methods for modulating cdk9 activity |
WO2023096922A1 (en) * | 2021-11-24 | 2023-06-01 | Kronos Bio, Inc. | Polymorphic and salt forms of (ls,3s)-n1-(5-(pentan-3- yl)pyrazolo[l,5-a]pyrimidin-7-yl)cyclopentane-l,3-diamine |
WO2024017365A1 (zh) * | 2022-07-22 | 2024-01-25 | 上海海雁医药科技有限公司 | 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389632A (en) | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
CN1046730C (zh) * | 1994-06-21 | 1999-11-24 | 株式会社大塚制药工场 | 吡唑并[1,5-a]嘧啶衍生物 |
DE69738197T2 (de) | 1996-07-24 | 2008-07-17 | Bristol-Myers Squibb Pharma Co. | Azolotriazine und pyrimidine |
US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
AU7737900A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
WO2001023387A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
JP2002308879A (ja) | 2001-04-13 | 2002-10-23 | Nippon Soda Co Ltd | 5−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤 |
CA2483306A1 (en) | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same |
JP2005529919A (ja) | 2002-05-10 | 2005-10-06 | スミスクライン ビーチャム コーポレーション | 治療用化合物 |
AU2003240488A1 (en) | 2002-06-04 | 2003-12-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7605155B2 (en) | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
TWI329645B (en) | 2002-09-04 | 2010-09-01 | Schering Corp | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
BRPI0314001B8 (pt) * | 2002-09-04 | 2021-05-25 | Merck Sharp & Dohme | pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas |
US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
GB0305559D0 (en) | 2003-03-11 | 2003-04-16 | Teijin Ltd | Compounds |
US20070179161A1 (en) | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
EP1671962A1 (en) | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
JP2007515474A (ja) | 2003-12-22 | 2007-06-14 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Crf受容体アンタゴニストおよびそれらに関連する方法 |
US8018479B2 (en) | 2008-08-27 | 2011-09-13 | Lexmark International, Inc. | Method and system for correcting the linearity error in electrophotographic devices |
KR20070051325A (ko) * | 2004-08-13 | 2007-05-17 | 데이진 화-마 가부시키가이샤 | 피라졸로[1,5-a]피리미딘 유도체 |
MX2007007604A (es) | 2004-12-21 | 2007-08-02 | Schering Corp | Antagonistas del receptor de pirazolo[1,5-a]pirimidina adenosina a2a. |
DE102005007534A1 (de) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
CN101360499B (zh) | 2005-10-06 | 2015-10-07 | 默沙东公司 | 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途 |
EP1931675B1 (en) | 2005-10-06 | 2015-01-14 | Merck Sharp & Dohme Corp. | Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors |
AU2006305104B2 (en) | 2005-10-21 | 2009-10-22 | Mitsubishi Tanabe Pharma Corporation | Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists |
WO2007109571A2 (en) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
JP2009538304A (ja) | 2006-05-22 | 2009-11-05 | シェーリング コーポレイション | CDK阻害剤としてのピラゾロ[1,5−a]ピリミジン |
EP2170073A4 (en) * | 2007-06-05 | 2011-07-27 | Univ Emory | SELECTIVE INHIBITORS FOR CYCLINE-RELATED KINASES |
CN101784276A (zh) | 2007-06-27 | 2010-07-21 | 传染性疾病研究院 | 化合物在用于制备抗结核药剂中的用途 |
US20110201599A1 (en) | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
WO2010074284A1 (ja) | 2008-12-26 | 2010-07-01 | 味の素株式会社 | ピラゾロピリミジン化合物 |
US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
ES2629170T3 (es) | 2009-12-04 | 2017-08-07 | Senhwa Biosciences, Inc. | Pirazolopirimidinas y heterociclos relacionados como inhibidores de CK2 |
RU2543386C2 (ru) | 2010-02-26 | 2015-02-27 | Мицубиси Танабе Фарма Коропорейшн | Производные пиразолопиримидина и их применение в качестве ингибиторов pde10 |
JP5688404B2 (ja) | 2010-03-05 | 2015-03-25 | 協和発酵キリン株式会社 | ピラゾロピリミジン誘導体 |
EP3012258B1 (en) | 2010-06-24 | 2018-09-19 | Gilead Sciences, Inc. | Pharmaceutical composition comprising a pyrazolo[1,5-a]pyrimidine derivative as an antiviral agent |
CA2802641C (en) | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2012044562A2 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
WO2012170827A2 (en) | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
JP6106694B2 (ja) | 2012-01-10 | 2017-04-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Aktキナーゼ阻害剤としての置換ピラゾロピリミジン類 |
KR20140123104A (ko) | 2012-02-17 | 2014-10-21 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 유비퀴틴 활성화 효소의 피라졸로피리미디닐 억제제 |
WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
US9573954B2 (en) | 2012-11-16 | 2017-02-21 | University Health Network | Pyrazolopyrimidine compounds |
BR112015022864A8 (pt) | 2013-03-14 | 2019-11-26 | Celtaxsys Inc | composto, composição farmacêutica e uso dos mesmos |
GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP3125907A4 (en) | 2014-04-01 | 2017-11-29 | Cornell University | Use of double-stranded dna in exosomes: a novel biomarker in cancer detection |
AU2015240518A1 (en) | 2014-04-05 | 2016-10-20 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
JP6789962B2 (ja) | 2015-03-09 | 2020-11-25 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | CDK阻害剤としてのピラゾロ[1,5−a][1,3,5]トリアジンとピラゾロ[1,5−a]ピリミジン誘導体 |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
WO2016169995A1 (en) | 2015-04-20 | 2016-10-27 | AbbVie Deutschland GmbH & Co. KG | Substituted pyrazolopyrimidines and method of use |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
KR20180056764A (ko) | 2015-10-01 | 2018-05-29 | 브리스톨-마이어스 스큅 컴퍼니 | 비아릴 키나제 억제제 |
JP2018199623A (ja) | 2015-10-22 | 2018-12-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
MX2018006195A (es) | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
WO2017180499A2 (en) | 2016-04-13 | 2017-10-19 | President And Fellows Of Harvard College | Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof |
WO2019023654A2 (en) * | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | DISCOVERING SMALL MOLECULES TARGETING THE ANDROGEN RECEPTOR AND USES THEREOF |
US11046698B2 (en) | 2017-07-28 | 2021-06-29 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
MA54092A (fr) * | 2018-10-30 | 2021-09-08 | Kronos Bio Inc | Composés, compositions et procédés de modulation de l'activité de cdk9 |
-
2019
- 2019-10-29 MA MA054092A patent/MA54092A/fr unknown
- 2019-10-29 SG SG11202104229WA patent/SG11202104229WA/en unknown
- 2019-10-29 MX MX2021004769A patent/MX2021004769A/es unknown
- 2019-10-29 KR KR1020217016498A patent/KR20210068597A/ko unknown
- 2019-10-29 CA CA3118472A patent/CA3118472A1/en active Pending
- 2019-10-29 JP JP2021521232A patent/JP7385658B2/ja active Active
- 2019-10-29 WO PCT/US2019/058482 patent/WO2020092314A1/en active Application Filing
- 2019-10-29 CN CN201980072853.7A patent/CN112996790B/zh active Active
- 2019-10-29 PE PE2021000604A patent/PE20212196A1/es unknown
- 2019-10-29 EP EP19878830.9A patent/EP3873911A4/en active Pending
- 2019-10-29 AU AU2019370200A patent/AU2019370200A1/en active Pending
- 2019-10-29 US US16/667,027 patent/US11155560B2/en active Active
- 2019-10-29 CR CR20210202A patent/CR20210202A/es unknown
- 2019-10-29 MD MDA20210033A patent/MD20210033A2/ro unknown
- 2019-10-29 BR BR112021008176-3A patent/BR112021008176A2/pt unknown
-
2021
- 2021-04-12 IL IL282254A patent/IL282254A/en unknown
- 2021-04-14 DO DO2021000066A patent/DOP2021000066A/es unknown
- 2021-04-15 PH PH12021550857A patent/PH12021550857A1/en unknown
- 2021-04-20 ZA ZA2021/02609A patent/ZA202102609B/en unknown
- 2021-04-27 CO CONC2021/0005502A patent/CO2021005502A2/es unknown
- 2021-09-15 US US17/476,237 patent/US11845754B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20220002305A1 (en) | 2022-01-06 |
AU2019370200A1 (en) | 2021-06-10 |
IL282254A (en) | 2021-05-31 |
ZA202102609B (en) | 2023-02-22 |
EP3873911A1 (en) | 2021-09-08 |
CR20210202A (es) | 2022-02-08 |
JP2022505268A (ja) | 2022-01-14 |
CN112996790A (zh) | 2021-06-18 |
KR20210068597A (ko) | 2021-06-09 |
SG11202104229WA (en) | 2021-05-28 |
US11845754B2 (en) | 2023-12-19 |
MD20210033A2 (ro) | 2021-10-31 |
WO2020092314A1 (en) | 2020-05-07 |
MA54092A (fr) | 2021-09-08 |
MX2021004769A (es) | 2021-08-24 |
DOP2021000066A (es) | 2021-10-31 |
BR112021008176A2 (pt) | 2021-08-03 |
US11155560B2 (en) | 2021-10-26 |
JP7385658B2 (ja) | 2023-11-22 |
CN112996790B (zh) | 2023-11-03 |
EP3873911A4 (en) | 2022-06-22 |
PH12021550857A1 (en) | 2021-12-06 |
PE20212196A1 (es) | 2021-11-16 |
US20200131189A1 (en) | 2020-04-30 |
CA3118472A1 (en) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021005502A2 (es) | Compuestos, composiciones, y métodos para modular la actividad cdk9 | |
CO2020007244A2 (es) | Inhibidores de kras g12c | |
CL2022000447A1 (es) | Inhibidores de kras g12d | |
UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
CU24612B1 (es) | Derivados de piridazinas sustituidas útiles como herbicidas | |
CU24621B1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
CR20130680A (es) | Métodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales i | |
UY37900A (es) | Nuevos derivados de rapamicina | |
ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
SV2018005656A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina,un proceso para su preparacion y composiciones farmaceuticas que los contiene | |
SV2009003216A (es) | Nuevos derivados de 1, 4-benzotiepina 1, 1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos, y su uso | |
PA8657501A1 (es) | Derivados de piperida y su uso como agentes antiinflamatorios | |
CU23834B1 (es) | Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9 | |
BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
ECSP19051352A (es) | Inhibidores selectivos de jak1 | |
CO6470826A2 (es) | Moduladores de lxr | |
GT200800285A (es) | Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden | |
UY37217A (es) | Síntesis de indazoles | |
CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
CU20180028A7 (es) | DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
CO2020012353A2 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos | |
CR20160029A (es) | Compuestos de pirimidino sustituido y derivados para combatir plagas de animales | |
CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
PE20210550A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico | |
CO2023017151A2 (es) | Inhibidores de ripk1 de nicotinamida |